-
2024-516741-39-00
6
2020-01-14
Haemophilia A
-
2023-508689-14-00
5
2019-09-16
Sickle cell disease
-
2024-517854-91-00
5
2019-08-05
Metastatic or high-risk recurrent prostate cancer managed with androge
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2023-506857-40-00
5
2019-01-08
Prostate Cancer
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2024-512701-11-00
4
2018-08-29
Systemic Juvenile Idiopathic Arthritis (sJIA)
-
2023-504880-18-00
9
2018-04-18
Neuroblastoma (NBL)
-
2024-517236-22-00
5
2017-09-20
Intradural saccular unruptured aneurysm
-
2023-508128-37-00
5
2017-07-19
All patients who have been treated with Novartis or Penn CAR T-cell th
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-516078-31-00
10
2015-05-05
Recurrent and Primary Refractory Ewing Sarcoma
-
2023-506027-29-00
5
2014-10-01
Children, adolescents and adults with newly diagnosed diffuse intrinsi
-
2024-518254-16-00
5
2013-03-01
Acute Myeloid Leukemia (Pediatric 0-18 years)
-
2025-520584-41-00
3
2026-03-10
Metabolism dysfunction
-
2024-519743-15-00
5
2025-10-20
Influenza immunisation
-
2025-520520-17-00
5
2025-09-05
Heterozygous familial hypercholesterolaemia
-
2024-516412-17-00
5
2025-08-26
Developmental and Epileptic Encephalopathies (DEE)
-
2024-517081-42-00
4
2025-08-15
Celiac Disease
-
2024-515524-36-00
5
2025-05-30
Chronic Weight Management
-
2024-516814-39-00
5
2025-05-20
Chronic rhinosinusitis with nasal polyps
-
2024-512925-95-00
5
2025-05-16
Advanced/Metastatic Breast Cancer
-
2023-505601-16-00
5
2025-04-22
Chronic Migraine
-
2023-510465-10-00
4
2025-03-10
Meningococcal immunization